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Abstract
While seven penicillin-binding proteins (PBPs) or PBP-like proteins have been identified either by
radiolabelled penicillin binding studies or genomic analysis, only PBP3 has been considered of
interest for Beta-lactams activity against Listeria monocytogenes. Herein we reveal that both PBP4
and Lmo0441 (a PBP-like protein) play a direct role in cephalosporin activity in L. monocytogenes
while PBP4 additionally has a protective affect against both penicillin and carbapenem.
Findings
The Gram-positive foodborne pathogen Listeria monocy-
togenes is a causative agent of gastroenteritis [1] and in
severe cases, listeriosis, which ranges from a mild flu-like
illness to meningitis in non-pregnant individuals, or as
infection of the foetus in pregnant women [2]. Ampicillin,
either alone or in combination with gentamicin, remains
the gold standard treatment for L. monocytogenes infection
[3]. Conversely, cephalosporins are usually poorly active
and thus not recommended in the treatment of listeriosis
[4,5]. This dissociation in susceptibilities between β-
lactams has been rationalized by the observation that
cephalosporins have poor affinity for PBP3 compared to
penicillin, suggesting that PBP3 is the primary lethal target
for β-lactams in L. monocytogenes [6]. However, at least five
different PBPs have been identified in L. monocytogenes
based on their ability to bind radioactive penicillin [6,7].
Moreover, genome analysis revealed seven distinct genes
with homologies to PBPs in L. monocytogenes [8]. With the
exception of pbpB, each of the remaining genes has been
disrupted by insertional mutagenesis [9] without loss of
cell viability, suggesting that they are not critically
required for normal synthesis of cell wall peptidoglycan.
Based on a previous study by Guinane et al., [9] in which
an increase in the activity of cephalosporins was observed
for L. monocytogenes disrupted in lmo2229 and lmo0441,
we investigated the role of their corresponding proteins
(PBP4 and Lmo0441 respectively) in protecting the path-
ogen against a penicillin (ampicillin, AMP), a carbap-
enem (meropenem, MEM) and a cephalosporin
(cefuroxime, CFX).
The growth rates for wild-type and mutant strains,
together with time profiles for the activity of AMP, MEM
and CFX at 100 times their MIC were tested over a 24 h
period in TSB broth (Fig. 1, left panel). No significant dif-
ferences in the growth rates were observed between wild
type and both mutant strains. However, this effect is only
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Activities of ampicillin (AMP), meropenem (MEM) and cefuroxime (CFX,) were tested against EGDe wild-type (triangle),  ΔPBP4 (squares) and ΔLmo0441 (circle) Figure 1
Activities of ampicillin (AMP), meropenem (MEM) and cefuroxime (CFX,) were tested against EGDe wild-
type (triangle), ΔPBP4 (squares) and ΔLmo0441 (circle). Left panel shows bacterial growth (open symbols, discontinu-
ous lines) and antibiotic activity (closed symbols and continuous lines) during 24h at 100 times MIC in TSB broth. Right panel 
shows, at 24h, the dose response curves of the 3 same antibiotics in TSB broth. Curve fitting and statistical analyses were per-
formed using GraphPad Prism for windows version 4.03 and GraphPad Instat version 3.01 (GraphPad® Software, San Diego, 
CA).Gut Pathogens 2009, 1:23 http://www.gutpathogens.com/content/1/1/23
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observed after an incubation of 24 h, the ΔPBP4 strain
appeared significantly more sensitive than the wild type to
both AMP and MEM, a phenotype not observed for the
ΔLmo0441 strain. In contrast, both PBP mutant strains
appeared less sensitive to CFX, after 24h, when compared
to the wild type strain, an unexpected result given their
MICs.
To better understand the role of PBP4 and Lmo0441 pro-
teins, full dose-response experiments were run with AMP,
MEM and CFX using a wide range of concentrations and
are presented in Fig. 1, right panel. Data collected were
used to determine the Hill function regression parameters
allowing the determination of the relative drug efficacy
(Emax) presented in Table 1. An increase of drug efficacy
was observed for AMP and MEM against the ΔPBP4 strain
(1.64 and 1.58 times the Emax of the parental wild-type
strain respectively); an effect which could not have been
predicted from MIC measurements; while Emax of AMP
and MEM were not affected in the ΔLmo0441 strain. In
contrast to the results obtained for AMP and MEM, both
PBPs mutant strains were affected by the activity of CFX
and in this case, a decrease of drug efficacy was observed
with the use of ΔPBP4 and ΔLmo0441 strains (0.63 and
0.53 times the Emax of the wild-type strain respectively).
In conclusion then, the construction of PBP mutant
strains ΔPBP4 and ΔLmo441 (Fig. 2) displayed no obvi-
ous growth defects in L. monocytogenes, suggesting that the
individual PBPs are most likely not essential for growth
under normal growth conditions. Furthermore, we dem-
onstrate a role for PBP4 in penicillin and carbapenem
activities in L. monocytogenes. Indeed, dose-response
experiments over a wide concentration range reveals an
increase in sensitivity of the ΔPBP4 strain for both AMP
and MEM compared to the parental wild-type strain. This
observation, which could not have been inferred from
MIC measurements alone, underscores the importance of
accurate techniques to predict antibiotic activity. Moreo-
ver, this effect appears specific to the ΔPBP4 strain and is
not apparent in the ΔLmo0441 mutant. The observed pro-
tective effect of PBP4 against penicillin and carbapenem
activities may result from decreased competition between
PBPs or from the loss of cooperative action with other
PBPs for the formation of the cell wall peptidoglycan.
This study also reveals that loss of PBP4 or Lmo0441 pro-
teins allows a decrease of maximal activity of cepha-
losporin, a class of antibiotics which, due to their poor
affinity for the PBP3, are not particularly effective against
L. monocytogenes [6]. This observation, which runs con-
Western Blot analysis of PBPs was performed as described  previously [10] with minor modifications Figure 2
Western Blot analysis of PBPs was performed as 
described previously [10]with minor modifications. 10 
ml of log phase bacteria (OD660 nm =0.5) were exposed to 
Bocillin FL (25 μg) for 30 min at 37°C. Bacteria were then 
harvested by centrifugation, washed four times with phos-
phate-buffered saline, and lysed by freeze-thawing process. 
Proteins were separated by 1D SDS-PAGE, and the acyl-
enzyme complex was detected (excitation: 488nm, emission: 
520nm) with a fluorescent scanner (Typhoon 9410, GE 
Healthcare). Mutagenesis results in a loss of bands of approx-
imately 75 and 78 KDa which correspond to the molecular 
weight of PBP4 and Lmo0441 proteins respectively.
Table 1: MIC measurements, regression parametersa and statistical analysis of the dose-response curves illustrated in Figure 1
AMP MEM CFX
MIC (mg/L) Emax
b (CI)c
Δlog from 
original inoculum
R2 MIC (mg/L) Emax
b (CI)c
Δlog from 
original inoculum
R2 MIC (mg/L) max
b (CI)c
log from original 
inoculum
R2
EGDe WT 0.125 -1.53 (-1.7 to -1.3) 0.97 0.0625 -1.85 (-2.2 to -1.5) 0.95 8 -3.65 (-4.2 to -3.1) 0.97
ΔPBP4 0.125 -2.51 (-2.7 to -2.3)d 0.98 0.0625 -2.92 (-3.3 to -2.5) d 0.98 2 -2.29 (-2.6 to -1.9) d 0.93
ΔLmo0441 0.125 -1.74 (-1.9 to -1.5) 0.97 0.0625 -2.02 (-2.5 to -1.6) 0.97 2 -1.92 (-2.2 to -1.7) d 0.95
Ampicillin (AMP), meropenem (MEM) and cefuroxime (CFX) MICs measurements for the parental strain EGDe and ΔPBP4 and ΔLmo0441 mutant 
strains. MICs of AMP and MEM, with a respective value of 0.125 and 0.0625 mg/L, did not differ between wild type and mutant strains. However, 
there is a 4-fold increase in MIC of CFX for both mutant strains, which passes from 8 mg/L to 2 mg/L, a finding which is in agreement with previous 
observations [9].
a Regression parameters are based on the Hill equation (using a variable slope)
b Concentration causing maximal activities (Emax values), as obtained from the Hill equation. Values are expressed as a multiple of the respective 
MIC for a given strain.
c CI - Confidence Intervals (95%)
d Significantly different (p < 0.05) from the wild type strain as calculated by F-testPublish with BioMed Central    and   every 
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trary to what was observed for AMP and MEM may be
explained by the fact that PBP3 may increase its relative
action in peptydoglycan synthesis when PBP4 or
lmo0441 are deleted: conferring resistance to cepha-
losporin. Thus, even if PBP3 remains the principal target
of β-lactam antibiotics, as is the current dictum, PBP4 and
Lmo0441 also appear to play an important role in the
activity of β-lactam antibiotics.
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